ANNUAL REPORT 2012

“Mom could still be with us today if more prevention policies, screening tests, and therapeutic options were available in 2010. Through awareness and prudent investments, we’ve figured out a path to decrease HPV-related cancer incidence dramatically in the coming decades.”

-- Camille Almada, Co-Founder

OUR MISSION

The HPV and Anal Cancer Foundation is dedicated to empowering anal cancer patients and accelerating prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, the carcinogen HPV (human papillomavirus). HPV is a skin virus that causes 5% of cancers worldwide.

We are committed to ending HPV-related cancers by investing in both scientific and support resources for patients, caregivers and researchers. We established the Foundation for our mother Paulette who passed away in 2010. Her strength, love, and memory continue to be the driving force behind all that we do.

IMPROVING SCREENING PROTOCOLS AND PREVENTATIVE CARE

Awarded a $50,000 grant to create the first anal cancer medical society. This seed grant was matched by the Farrah Fawcett Foundation. The International Anal Neoplasia Society (IANS) brings scientists and clinicians together to discuss prevention, treatment, and novel therapies in forums dedicated exclusively to anal precancer and cancer. IANS is committed to generating and disseminating knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal cancer and precancer.

To improve patient quality of life and survivorship, it is essential to advance anal neoplasia awareness on the clinician and patient level. The enormous lack of education often leads to late diagnoses and poor outcomes for people at risk for anal disease. IANS will hold the first ever scientific conference on anal cancer in November 2013.
RAISING AWARENESS, DESTIGMITIZING ANAL CANCER, AND EMPOWERING THRIVERS

The Foundation and GMHC co-sponsored a pioneering anal cancer forum, *The Cancer That Dare Not Speak Its Name: A Community Discussion on Anal Cancer*. One of our founders, Camille Almada, served as a member of the five person panel that discussed anal cancer stigma, prevention, screening, treatment, and advocacy. This panel and others like it are instrumental in helping to educate the public, reduce stigma, and unite the anal cancer community.

THE FOUNDATION GOES GLOBAL

Consistent with our mission to reduce global suffering from anal cancer and the virus that causes the majority of its cases, HPV, we are happy to announce that the HPV and Anal Cancer Foundation has registered as a charity in England and Wales (Charity No. 1147457).

The HPV and Anal Cancer Foundation aims to galvanize a global community of people working together for the same goal: preventing, identifying, and treating anal cancer and other HPV-associated diseases. The more people we connect to the cause, the greater chance we have in succeeding in our mission.

Broadening the conversation to the European continent is essential to improving awareness for the disease across a wide range of stakeholders: public officials, clinicians, scientists, patients and their families.

FINANCIALS

**2012 Statement of Activities**

<table>
<thead>
<tr>
<th>Support and Revenues</th>
<th>$138,079</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and Grants</td>
<td></td>
</tr>
<tr>
<td>Expenses</td>
<td></td>
</tr>
<tr>
<td>Education and Advocacy Programs</td>
<td>$54,031</td>
</tr>
<tr>
<td>Management and General</td>
<td>$16,194</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$70,225</td>
</tr>
<tr>
<td>Change in Net Assets</td>
<td>$67,854</td>
</tr>
<tr>
<td>Net Assets, Beginning of Year</td>
<td>$142,571</td>
</tr>
<tr>
<td>Net Assets, End of Year</td>
<td>$210,425</td>
</tr>
</tbody>
</table>

WITH GRATITUDE

2012 was a breakthrough year for The HPV and Anal Cancer Foundation. It was with the help of our generous donors that we were able to grow our community and provide new platforms and avenues for researchers. The milestones of 2012 would not have been possible without our donors. Thank you!
TOMORROW’S FOUNDATION
As the Foundation and community grow, we are able to expand our ventures. Here is what we have planned for 2013:

- **HPVTrialFinder.org** - A platform to match patients and clinical trials. This initiative would result in faster decisions concerning the availability of certain drugs.

- **Investigator Seed Grant** - Provide researchers with the incentive and ability to test hypotheses and collect data regarding HPV-related cancer. This will garner larger, sustained funding sources.

- **Cell Line Prize** - Scientists have made clear to us they need cell lines as a first step to find better drugs for anal cancer patients. No anal cancer cell lines exist. This competition would develop immortal anal cancer lines.

- **FDA Drug Repurposing** - Test the anal cancer lines we develop against previously approved compounds.

- **HPVAction.org** - An advocacy platform for gender-neutral vaccination.

- **Patient Support Services** - The isolation and stigma associated with anal cancer is unique, and few survivors ever meet or speak with someone else who has experienced the disease. The peer support program gives thrivers a person to listen, offer support, and share experiences.

BOARD OF DIRECTORS
Camille Almada
Justine Almada
Tristan Almada
Jesper Bo Hansen
Nicoletta Bumbac
Christian Levett
William Schoneman

SCIENTIFIC ADVISORY BOARD
Cathy Eng, M.D., F.A.C.P.
The University of Texas M. D. Anderson Cancer Center

Paul F. Lambert, Ph.D.
University of Wisconsin, School of Medicine and Public Health

Karl Munger, Ph.D.
Harvard Medical School

Joel Palefsky, M.D., C.M., F.R.C.P.(C)
University of California, San Francisco